[{"id":"91ee3393-64e6-45b8-85ff-2a95ec6c2795","acronym":"","url":"https://clinicaltrials.gov/study/NCT03053466","created_at":"2021-01-18T15:02:20.220Z","updated_at":"2024-07-02T16:36:10.795Z","phase":"Phase 1","brief_title":"APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors","source_id_and_acronym":"NCT03053466","lead_sponsor":"Apollomics (Australia) Pty. Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aibining (geptanolimab)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 02/25/2022","primary_completion_date":" 02/25/2022","study_txt":" Completion: 02/25/2022","study_completion_date":" 02/25/2022","last_update_posted":"2022-05-09"},{"id":"76d86b1d-e25a-4d4f-8b33-b4b6f815b66f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03374007","created_at":"2021-01-18T16:39:08.163Z","updated_at":"2024-07-02T16:36:26.314Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma","source_id_and_acronym":"NCT03374007","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aibining (geptanolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/19/2017","start_date":" 10/19/2017","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-08-16"},{"id":"a0ffee0e-2841-4ebf-a85b-469d84ecae57","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808857","created_at":"2021-01-18T18:49:18.318Z","updated_at":"2024-07-02T16:36:33.843Z","phase":"Phase 2","brief_title":"A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive","source_id_and_acronym":"NCT03808857","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aibining (geptanolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/23/2019","start_date":" 05/23/2019","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2021-03-03"}]